anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Twenty-three healthy adults with normal weight and twenty-three healthy adults with overweight consumed a standardized breakfast after a 12-hour fast. Two hours later they were given 50 g of available carbohydrates from the two preloads (enriched orange juice or control orange juice) in a random order, and 3 hours after the preload they were offered an ad libitum lunch. Foods were weighed at the time of serving and any leftovers were weighed again after lunch to determine the amount of food consumed. There was a washout period of at least one week between the two visits. Fingertip capillary blood glucose samples were collected at baseline and at several time points after food intake. Visual analog scales (VAS) of 100 mm were collected to assess subjective appetite. Blood pressure was measured at several time-points.
In a family with Familial Non-Medullary Thyroid Carcinoma (FNMTC), our investigation using Whole-Exome Sequencing (WES) uncovered a novel germline USP42 mutation [p.(Gly486Arg)]. USP42 is known for regulating p53, cell cycle arrest, and apoptosis, and for being reported as overexpressed in breast and gastric cancer patients. Recently, a USP13 missense mutation was described in FNMTC, suggesting a potential involvement in thyroid cancer. Aiming to explore the USP42 mutation as an underlying cause of FNMTC, our team validated the mutation in blood and tissue samples from the family. Using immunohistochemistry, the expression of USP42, Caspase-3, and p53 was assessed. The USP42 gene was silenced in human thyroid Nthy-Ori 3-1 cells using siRNAs. Subsequently, expression, viability, and morphological assays were conducted. p53, Cyclin D1, p21, and p27 proteins were evaluated by Western blot. USP42 protein was confirmed in all family members and was found to be overexpressed in tumor samples, along with an increased expression of p53 and cleaved Caspase-3. siRNA-mediated USP42 downregulation in Nthy-Ori 3-1 cells resulted in reduced cell viability, morphological changes, and modifications in cell cycle-related proteins. Our results suggest a pivotal role of USP42 mutation in thyroid cell biology, and this finding indicates that USP42 may serve as a new putative target in FNMTC.
Depot medroxyprogesterone acetate (DMPA) is a generic form of the DepoProvera® shot. When receiving the birth control shot some girls gain a lot of weight while others do not. Some girls also lose bone mineral density (BMD). Bone mineral density is the amount of weight and thickness of the bones.

In this study 1 of 3 doses of DMPA will be given as an injection into the muscle in the arm. The 150mg dose is approved for use in this age group by the Food and Drug Administration (FDA) when given into the muscle. The 104mg dose is approved for use in this age group by the FDA only when given under the skin therefore it is considered experimental. The 75mg dose is also considered experimental as this dose is not FDA approved regardless of how it is given.
Seizures, antiseizure medications, and the reproductive systems are reciprocally entwined. In Section 2 of this review, we outline how seizures may affect the hypothalamic-pituitary-gonadal axis, thereby altering sex steroids, and changes in sex steroids across the menstrual cycle and changes in pharmacokinetics during pregnancy may alter seizure susceptibility. The literature indicates that females with epilepsy experience increased rates of menstrual disturbances and reproductive endocrine disorders. The latter include polycystic ovary syndrome, especially for females on valproate. Studies of fertility have yielded mixed results. We aim to summarize and attempt to detangle the existing knowledge on these reciprocal interactions. The menstrual cycle causes changes in seizure intensity and frequency for many females. When this occurs perimenstrually, during ovulation, or in association with an inadequate luteal phase, it is termed catamenial epilepsy. There is a clear biophysiological rationale for how the key female reproductive neurosteroids interact with the brain to alter the seizure threshold, and Section 3 outlines this important relationship. Critically, what remains unknown is the specific pathophysiology of catamenial epilepsy that describes why not all females are affected. There is a need for mechanism-focused investigations in humans to uncover the complexity of the relationship between reproductive hormones, menstrual cycles, and the brain.
A single domain antibody against CLD18 A2. The complementarity determining region of the anti-CLD 18A2 single domain antibody comprises CDR-H1 with the amino acid sequence shown as one of SEQ ID NO. 4-11, CDR-H2 with the amino acid sequence shown as one of SEQ ID NO. 19-26 and CDR-H3 with the amino acid sequence shown as one of SEQ ID NO. 33-39. The single domain antibody of the anti-CLD 18A2 has good affinity for Claudin18.2, can be used for further constructing bispecific antibodies, antibody-drug complexes, chimeric antigen receptors and the like, and has good targeting and killing effects on target cells for the bispecific antibodies, antibody-drug complexes, CAR-T cells and the like.
In the past, polyacrylamide hydrogel was a popular choice for breast augmentation filler, and many women underwent mammoplasty with this gel. However, due to frequent complications, the use of polyacrylamide hydrogel in mammoplasty has been banned. Despite this ban, patients experiencing complications still seek medical treatment. The aim of this study was to investigate the fate of the polymer over a defined implantation period. Biopsies of breast implants were obtained from patients with 23 and 27 years of post-mammoplasty. These biopsies were meticulously purified from biological impurities and subjected to analysis using IR spectrometry, liquid chromatography-mass spectrometry, gas chromatography, and differential scanning calorimetry. The findings revealed the presence of polyacrylamide hydrogel residues, along with degradation products, within the infected material. Notably, the low-molecular-weight degradation products revealed via gas chromatography are aggressive and toxic substances capable of inducing chronic inflammation. This study sheds light on the long-term consequences of polyacrylamide hydrogel implantation, highlighting the persistence of harmful degradation products and their role in exacerbating patient complications.
An aqueous dispersion of a tertiary aminoalkyl ether of starch having the formula <FORM:1015935/C3/1> wherein X is starch containing 25 to 50 parts by weight of amylose and 75 to 50 parts by weight of amylopectin, R is alkylene or hydroxyalkylene, and R1 and R2 are alkyl, aralkyl or aryl radicals, the starch ether containing 0.25 to 2.0% by weight of nitrogen, is heated at 75 to 85 DEG  C. for 25 to 30 minutes until a gelatinous solution results, and the solution is cooled to 25 DEG  to 27 DEG  C.  The starch ethers may be made by reacting ungelatinized starch with, for example, a dialkylaminoethyl chloride in alkylene medium.  The gelatinized starch ether solutions are used alone, or as in admixture with other ingredients, as hair-setting compositions (Divisions A5 and D1).ALSO:A method of setting hair comprises applying to the hair a composition comprising a gelatinous aqueous dispersion of a tertiary aminoalkyl starch ether of formula: <FORM:1015935/D1-D2/1> where y is starch containing 25-50 parts by weight of amylose and 75-50 parts by weight of amylopecton, R is alkylene or hydroxyalkylene, and R1 and R2 are alkyl, aryl, or aralkyl, the starch ether containing 0.25-2.0% of nitrogen, shaping the hair to the required configuration, and allowing the water to evaporate.  The composition may also include conditioners, humectants, preservatives, plasticizers or perfumes.  Specified additives are stearyl ester of cholaminoformyl pyridinium chloride, stearyl dimethylbenzyl ammonium chloride, ethoxylated lanolin, cationic long-chain fatty amines, glycerol, sorbitol, propylene glycol, urea and formaldehyde.ALSO:A hair-setting composition comprises a gelatinous aqueous dispersion of a tertiary aminoalkyl starch ether of formula <FORM:1015935/A5-A6/1> where X is starch containing 25 to 50 parts by weight of amyloze and 75 to 50 parts by weight of amylopectin, R is alkylene or hydroxy-alkylene and R1 and R2 are alkyl, aryl or aralkyl radicals, the starch ether containing 0.25 to 2.0% by weight of nitrogen.  The composition may also contain a hair conditioning agent e.g. a stearyl ester of cholaminoformylmethyl pyridinium chloride, stearyl, dimethylbenzyl ammonium chloride, ethoxylated lanolin or a cationic long-chain fatty amine; a humictant e.g. glycerol, sorbitol, or propylene glycol; a plasticizer e.g. urea; a preservative e.g. formaldehyde; and a perfume.
PURPOSE:To make it possible to monitor whether antitumor effect can be expected or not in a clinical way when host intervening anticancer agent is used for a patient by containing lentinan or Sonifiran. CONSTITUTION:This assay medicine contains lentinan or Sonifiran. When the lentinan as the amount of anticancer agent is administered, blood-vessel permeability rises up. Then, the macrophage in the organism is activated by the administering of the lentinan, and the second path of the complement is also activated. The complicated biological reaction caused by various freed mediators occurs. As a result, the blood-vessel peremeability is changed. It is estimated that the occurrence of the reaction such as this at the local tumor position is related to the apperance of the antitumor effect. Therefore, the antitumor effect can be judged by inspecting the change in reaction in tumor sample, which is obtained by surgically extracting the same reaction and the change in intracutaneous reaction of patient.
Dispense in the original sealed carton with the enclosed Instructions for Use.

Store Insulin Degludec vials in the original carton to protect from light. Store unused Insulin Degludec in a refrigerator (36ºF to 46ºF [2ºC to 8ºC]). Do not store in the freezer or directly adjacent to the refrigerator cooling element. Do not freeze. Do not use Insulin Degludec if it has been frozen.

The storage conditions are summarized in Table 18:

Table 18: Storage Conditions for Insulin Degludec
The invention belongs to the fields of chemical engineering and medicines, and relates to the application of solasodine in preparing antitumor medicines. The invention provides the application of solasodine in preparing antitumor medicines. The tumor cells comprise liver cancer cells, blood cancer cells, cervical cancer cells, breast cancer cells, and pancreatic cancer cells. Solasodine is a natural product with low toxic and side effect, high bioavailability, stable quality, and clinical application values. A small-molecular compound provided by the invention is developed as a novel antitumor medicine or an auxiliary component thereof. A tumor inhibiting effect is substantial, and the compound is green and environment-friendly. Therefore, novel approach and means are provided for treating and curing tumors.
The reabsorption of uric acid (UA) is mainly mediated by urate transporter 1 (URAT1) and glucose transporter 9 (GLUT9) in the kidneys. Dotinurad inhibits URAT1 but does not inhibit other UA transporters, such as GLUT9, ATP-binding cassette transporter G2 (ABCG2), and organic anion transporter 1/3 (OAT1/3). We found that dotinurad ameliorated the metabolic parameters and renal function in hyperuricemic patients. We consider the significance of the highly selective inhibition of URAT1 by dotinurad for metabolic syndrome, chronic kidney disease (CKD), and cardiovascular disease (CVD). The selective inhibition of URAT1 by dotinurad increases urinary UA in the proximal tubules, and this un-reabsorbed UA may compete with urinary glucose for GLUT9, reducing glucose reabsorption. The inhibition by dotinurad of UA entry via URAT1 into the liver and adipose tissues increased energy expenditure and decreased lipid synthesis and inflammation in rats. Such effects may improve metabolic parameters. CKD patients accumulate uremic toxins, including indoxyl sulfate (IS), in the body. ABCG2 regulates the renal and intestinal excretion of IS, which strongly affects CKD. OAT1/3 inhibitors suppress IS uptake into the kidneys, thereby increasing plasma IS, which produces oxidative stress and induces vascular endothelial dysfunction in CKD patients. The highly selective inhibition of URAT1 by dotinurad may be beneficial for metabolic syndrome, CKD, and CVD.
Disclosed is a contactless event monitoring and early detection method and system of real time monitoring of a person to predict an undesired event. The contactless event monitoring and early detection method collects data from a one or more data aggregation devices and filters the collected data in a signal processor. The contactless event monitoring and early detection method then analyzes the collected data in an event monitoring and detection processor. The event monitoring and detection processor implementing artificial intelligence algorithms to predict the probability of the occurrence of to the undesired event. Further, the event monitoring and detection processor receives a health data related to the person and selects an analytical model to be applied for prediction of the undesired event. In one embodiment, the probability of occurrence of the undesired event is associated on a threshold value. The threshold value is related to at least one early indicator associated with the person. The contactless event monitoring and early detection method then preempts the person about the onset of the undesired event by sending an alert to the person and a caretaker for remedial action.
Participants will float in a shallow pool of water with about 1000 pounds of epsom salt, in a light and sound attenuated device, for up to 60 minutes. Following the session, participants' ratings of the experience will be measured.
Dietary sodium restriction increases plasma triglycerides (TG) and total cholesterol (TC) concentrations as well as causing insulin resistance and stimulation of the renin-angiotensin-aldosterone system (RAAS) and the sympathetic nervous system. Stimulation of the angiotensin II type-1 receptor (AT1) is associated with insulin resistance, inflammation, and the inhibition of adipogenesis. The current study investigated whether aerobic exercise training (AET) mitigates or inhibits the adverse effects of dietary sodium restriction on adiposity, inflammation, and insulin sensitivity in periepididymal adipose tissue. LDL receptor knockout mice were fed either a normal-sodium (NS; 1.27% NaCl) or a low-sodium (LS; 0.15% NaCl) diet and were either subjected to AET for 90 days or kept sedentary. Body mass, blood pressure (BP), hematocrit, plasma TC, TG, glucose and 24-hour urinary sodium (UNa) concentrations, insulin sensitivity, lipoprotein profile, histopathological analyses, and gene and protein expression were determined. The results were evaluated using two-way ANOVA. Differences were not observed in BP, hematocrit, diet consumption, and TC. The LS diet was found to enhance body mass, insulin resistance, plasma glucose, TG, LDL-C, and VLDL-TG and reduce UNa, HDL-C, and HDL-TG, showing a pro-atherogenic lipid profile. In periepididymal adipose tissue, the LS diet increased tissue mass, TG, TC, AT1 receptor, pro-inflammatory macro-phages contents, and the area of adipocytes; contrarily, the LS diet decreased anti-inflammatory macrophages, protein contents and the transcription of genes related to insulin sensitivity. The AET prevented insulin resistance, but did not protect against dyslipidemia, adipose tissue pro-inflammatory profile, increased tissue mass, AT1 receptor expression, TG, and TC induced by the LS diet.
This is a multicenter, open-label (participants will know the identity of study drug received) study in participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC). The study is a single sequence design (ie, all participants will take abiraterone acetate + prednisone \[AAP\] once daily on Days 1-7 of Treatment Cycle 1 and then proceed with combined daily intake of AAP+JNJ-56021927 from Treatment Cycle 1, Day 8 through to the end of treatment \[ie, for up to an expected duration of approximately 18 months\] and will be conducted as two cohorts (group of participant's). The study will consist of a 28-day screening phase to determine eligibility, an open-label treatment phase consisting of 28-day treatment cycles, and a 30-day follow-up phase for collection of adverse events (AE) after last dose of study drug. Participants will have blood samples collected during the study to evaluate pharmacokinetics, safety, and antitumor activity (PSA). Participant safety will also be monitored by the collection of adverse events. Imaging assessments for disease evaluation will be planned at discretion of the Investigator. Once all participants have completed study treatment up to Cycle 3 Day 1, a data cutoff is planned to evaluate the short term safety profile of the combination and to complete the PK analysis up to the cutoff date. All participants will continue on study (ie, to receive treatment) until disease progression, withdrawal of consent, lost to follow-up, or the occurrence of unacceptable toxicity. The end of the study is defined when all participants have completed treatment. Participant's safety will be monitored throughout the study.
In the parachute technique, suture was first secured at 11 o'clock position entering both vessels in an inside-out fashion, then continuous suturing was commenced towards 5 o'clock position across the heel, entering the vein outside-in and the artery inside-out, without approximating the vessels. Then, gentle traction was applied on the sutures to allow even distribution of tension along the suture-line and 'parachuting' or approximation of vessel walls together. The suture was then run in a continuous fashion across the proximal margin (toward surgeon) and across the toe region, and finally, surgical knots were applied at midway on the distal margin.
The purpose of this study is to translate the Italian APA exercise model into a sustainable, evidence-based VA community program of exercise for older adults with chronic stroke. The investigators' short-term objectives are to test study hypotheses using a Randomized Clinical Trial (RCT) with an Attention Control (also referred to as the "Sittercise" exercise program). The investigators will also explore factors related to exercise adherence in a community program for chronic stroke survivors. The investigators' longer term objective is to disseminate this model to facilitate the development of a network of community-based exercise programs for older adults with chronic stroke. In the RCT the investigators propose to offer courses in Office of Aging (OoA) Senior Centers and National Rehabilitation Hospital. At the conclusion of the research study, the OoA plans to continue offering APA-stroke courses. Through partnership, the Veterans Health Administration (VHA) and the Administration of Aging (AoA) can potentially replicate this model at the community throughout the U.S. using local OoA Senior Centers and other facilities that would increase community access for Veterans.
AIM: To evaluate the effects of surgical timing on the prognosis in far lateral disk herniations.
MATERIAL AND METHODS: We retrospectively evaluated 171 patients diagnosed with far lateral disk herniation who underwent surgery between 2015 and 2021. Patients were divided into three groups: Those operated within the first 3 weeks, within 3-6 weeks, and after 6 weeks. Patients with progressive neurologic deficits and severe pain refractory to the analgesic treatment underwent surgery.
RESULTS: The mean age was 57±3 (28-85) years. The patients consisted of 96 females and 75 males. Sixty-eight patients underwent surgery at the L4-L5, 45 at the L3-L4, 37 at the L5-S1, and 21 at L2-3 levels. All patients had low back and radicular leg pain. Lasegue test was positive in 67% of patients. Femoral nerve stretch test was positive in 68%. Motor deficits, patellar reflex loss, and sensory deficits were present in 76%, 80%, and 91% respectively. When the postoperative recovery rates of patients who underwent surgery in all three time periods were compared according to visual analog scale, Oswestry disability index, and MacNab criteria, notably, statistically significant improvements in recovery were observed among patients who underwent surgery in the preoperative short time period when compared to those in the other time periods.
CONCLUSION: We believe that early surgery is important to prevent the progression of pain from acute to chronic neuropathic pain to promptly eliminate factors that activate the process and to provide faster and clearer symptom treatment.
PROBLEM TO BE SOLVED: To obtain a cosmetic, quasi-medicine, medicine and food having an excellent bleaching action by including a specific substance having an inhibitory action of tyrosinase. SOLUTION: This cosmetic contains a substance of formula I (n is 1-20; R1 to R8 are each H or OH) (e.g. prodelphinidin, proapigeninidin, etc.). The compound of formula I is obtained, for example, by dissolving a compound of formula II (e.g. naringenin, ampeloptin, etc.), in a solvent such as ethanol, etc., adding sodium borohydride of 2-5 times mol numbers of the compound of formula II, degassing the solution, stirring for two hours, adding water, adjusting the solution to pH about 7, adding a compound of formula III (e.g. catechin, etc.), (equimolar amount to 1/20 mol based on the compound of formula II) dissolved in a solvent, adjusting the solution to pH 3-4 with an acid and stirring for 24-50 hours. A raw material for a cosmetic, quasi-medicine, medicine or food is formulated with the substance to give a product effective for bleaching.